Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Executive Summary
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
You may also be interested in...
Celltrion Wins Korea Approval For Roche Herceptin Biosimilar
Celltrion gains approval for its second monoclonal antibody biosimilar following a biosimilar of Johnson & Johnson’s Remicade. The approval marks the second entry of a Herceptin biosimilar and the first based on global clinical trials, but Roche believes it is adequately protected against the competition.
Celltrion Wins Korea Approval For Roche Herceptin Biosimilar
Celltrion gains approval for its second monoclonal antibody biosimilar following a biosimilar of Johnson & Johnson’s Remicade. The approval marks the second entry of a Herceptin biosimilar and the first based on global clinical trials, but Roche believes it is adequately protected against the competition.
Korea’s Celltrion Dismisses As Rumor Reports That AstraZeneca, Roche And Teva Are Interested Buyers
Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.